Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: An analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort

Barbara I. Gulanski, Nicole M. Butera, Heidi Krause-Steinrauf, Judith H. Lichtman, Tasma Harindhanavudhi, Jennifer B. Green, Colleen E. Suratt, Hiba Abouassi, Cyrus Desouza, Andrew J. Ahmann, Deborah J. Wexler, Vanita R. Aroda

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Introduction Type 2 diabetes mellitus (T2DM) is a powerful risk factor for cardiovascular disease (CVD), conferring a greater relative risk in women than men. We sought to examine sex differences in cardiometabolic risk factors and management in the contemporary cohort represented by the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Research design and methods GRADE enrolled 5047 participants (1837 women, 3210 men) with T2DM on metformin monotherapy at baseline. The current report is a cross-sectional analysis of baseline data collected July 2013 to August 2017. Results Compared with men, women had a higher mean body mass index (BMI), greater prevalence of severe obesity (BMI≥40 kg/m 2), higher mean LDL cholesterol, greater prevalence of low HDL cholesterol, and were less likely to receive statin treatment and achieve target LDL, with a generally greater prevalence of these risk factors in younger women. Women with hypertension were equally likely to achieve blood pressure targets as men; however, women were less likely to receive ACE inhibitors or angiotensin receptor blockers. Women were more likely to be divorced, separated or widowed, and had fewer years of education and lower incomes. Conclusions This contemporary cohort demonstrates that women with T2DM continue to have a greater burden of cardiometabolic and socioeconomic risk factors than men, particularly younger women. Attention to these persisting disparities is needed to reduce the burden of CVD in women. Trial registration number ClinicalTrials.gov

Original languageEnglish (US)
Article numbere003159
JournalBMJ Open Diabetes Research and Care
Volume11
Issue number2
DOIs
StatePublished - Apr 24 2023

Bibliographical note

Funding Information:
The GRADE Study is supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health under Award Number U01DK098246. The planning of GRADE was supported by a U34 planning grant from the NIDDK (U34-DK-088043). The American Diabetes Association supported the initial planning meeting for the U34 proposal. The National Heart, Lung, and Blood Institute and the Centers for Disease Control and Prevention also provided funding support. The Department of Veterans Affairs provided resources and facilities. Additional support was provided by grant numbers P30 DK017047, P30 DK020541-44, P30 DK020572, P30 DK072476, P30 DK079626, P30 DK092926, U54 GM104940, UL1 TR000439, UL1 TR000445, UL1 TR001108, UL1 TR001409, UL1 TR001449, UL1 TR002243, UL1 TR002345, UL1 TR002378, UL1 TR002489, UL1 TR002529, UL1 TR002535, UL1 TR002537, UL1 TR001425 and UL1 TR002548. Educational materials have been provided by the National Diabetes Education Program. Material support in the form of donated medications and supplies has been provided by Becton, Dickinson and Company, Bristol-Myers Squibb, Merck, NovoNordisk, Roche Diagnostics, and Sanofi. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.

Keywords

  • Diabetes Mellitus, Type 2
  • Evidence-Based Medicine
  • Risk Factors
  • Women's Health

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: An analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort'. Together they form a unique fingerprint.

Cite this